RU2016134838A - Дипептидил пептидаза-4 (dpp4/cd26) как периферический биомаркер активации il-13 в астматическом легком - Google Patents
Дипептидил пептидаза-4 (dpp4/cd26) как периферический биомаркер активации il-13 в астматическом легком Download PDFInfo
- Publication number
- RU2016134838A RU2016134838A RU2016134838A RU2016134838A RU2016134838A RU 2016134838 A RU2016134838 A RU 2016134838A RU 2016134838 A RU2016134838 A RU 2016134838A RU 2016134838 A RU2016134838 A RU 2016134838A RU 2016134838 A RU2016134838 A RU 2016134838A
- Authority
- RU
- Russia
- Prior art keywords
- dpp4
- patient
- level
- asthma
- seq
- Prior art date
Links
- 102000003816 Interleukin-13 Human genes 0.000 title claims 27
- 108090000176 Interleukin-13 Proteins 0.000 title claims 27
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 title claims 24
- 208000006673 asthma Diseases 0.000 title claims 15
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 title 3
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 title 2
- 230000004913 activation Effects 0.000 title 1
- 239000000090 biomarker Substances 0.000 title 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 title 1
- 230000002093 peripheral effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 claims 28
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 23
- 239000000427 antigen Substances 0.000 claims 17
- 102000036639 antigens Human genes 0.000 claims 17
- 108091007433 antigens Proteins 0.000 claims 17
- 239000012634 fragment Substances 0.000 claims 17
- 239000005557 antagonist Substances 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 239000003246 corticosteroid Substances 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 6
- 239000000523 sample Substances 0.000 claims 6
- 229950000835 tralokinumab Drugs 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- 229960001334 corticosteroids Drugs 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 150000003431 steroids Chemical class 0.000 claims 3
- 208000019693 Lung disease Diseases 0.000 claims 2
- 102100037765 Periostin Human genes 0.000 claims 2
- 101710199268 Periostin Proteins 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 229940124630 bronchodilator Drugs 0.000 claims 2
- 229940112141 dry powder inhaler Drugs 0.000 claims 2
- 210000003979 eosinophil Anatomy 0.000 claims 2
- 238000010324 immunological assay Methods 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 239000013610 patient sample Substances 0.000 claims 2
- 229940068196 placebo Drugs 0.000 claims 2
- 239000000902 placebo Substances 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 208000000592 Nasal Polyps Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical group CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000023819 chronic asthma Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 238000002591 computed tomography Methods 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 208000024711 extrinsic asthma Diseases 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 229960002052 salbutamol Drugs 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- 229940127211 short-acting beta 2 agonist Drugs 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 239000010802 sludge Substances 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5437—IL-13
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/202—Dermatitis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461931878P | 2014-01-27 | 2014-01-27 | |
| US61/931,878 | 2014-01-27 | ||
| US201461990932P | 2014-05-09 | 2014-05-09 | |
| US61/990,932 | 2014-05-09 | ||
| PCT/US2015/012885 WO2015112970A1 (en) | 2014-01-27 | 2015-01-26 | Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016134838A true RU2016134838A (ru) | 2018-03-07 |
| RU2016134838A3 RU2016134838A3 (cg-RX-API-DMAC7.html) | 2018-09-27 |
Family
ID=53682019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016134838A RU2016134838A (ru) | 2014-01-27 | 2015-01-26 | Дипептидил пептидаза-4 (dpp4/cd26) как периферический биомаркер активации il-13 в астматическом легком |
Country Status (12)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9862762B2 (en) | 2014-02-07 | 2018-01-09 | Medimmune, Llc | Monoclonal antibodies which bind human periostin |
| EP3242686B1 (en) | 2015-01-09 | 2020-07-08 | Medimmune, LLC | Assay to detect human dpp-4 |
| JP2018538249A (ja) * | 2015-11-04 | 2018-12-27 | アストラゼネカ アクチボラグ | 好酸球性疾患における好酸球標的化治療薬に対する臨床応答の予測変数としてのジペプチジルペプチダーゼ−４およびペリオスチン |
| EA037960B1 (ru) | 2016-04-27 | 2021-06-15 | Эббви Инк. | Способ лечения эозинофильного эзофагита с применением антитела против il-13 |
| CN107474134B (zh) | 2016-06-08 | 2021-07-27 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| IL265473B2 (en) * | 2016-09-23 | 2024-01-01 | Genentech Inc | Uses of il-13 antagonists for treating atopic dermatitis |
| US10386368B2 (en) | 2017-02-24 | 2019-08-20 | Trustees Of Boston University | Isolation of human lung progenitors derived from pluripotent stem cells |
| CN109055522A (zh) * | 2018-07-03 | 2018-12-21 | 吉林大学 | C4orf38在制备用于检测或治疗神经性疼痛的产品中的应用 |
| WO2020096381A1 (ko) | 2018-11-09 | 2020-05-14 | 아주대학교 산학협력단 | 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도 |
| CN113155996A (zh) * | 2021-03-23 | 2021-07-23 | 广州医科大学附属第一医院（广州呼吸中心） | 15(s)-羟基二十碳四烯酸在评估变应原特异性免疫治疗效果中的应用 |
| PE20251639A1 (es) | 2022-06-17 | 2025-06-24 | Apogee Biologics Inc | Anticuerpos que se unen a interleuquina 13 y metodos de uso |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| EP1631680A2 (en) * | 2003-05-21 | 2006-03-08 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4) |
| GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| JP4980878B2 (ja) * | 2004-02-23 | 2012-07-18 | エラスムス ユニバーシティ メディカル センター ロッテルダム | 遺伝子発現プロファイリングによる急性骨髄性白血病の分類、診断、および予後 |
| WO2008073463A2 (en) * | 2006-12-11 | 2008-06-19 | Wyeth | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
| US20090155784A1 (en) * | 2007-01-22 | 2009-06-18 | Wyeth | Assessment of asthma and allergen-dependent gene expression |
| WO2008097198A1 (en) * | 2007-02-09 | 2008-08-14 | Agency For Science, Technology And Research | Apparatus and method for analysis of data traffic |
| DK2644713T3 (en) * | 2007-10-23 | 2018-08-20 | Clinical Genomics Pty Ltd | A Method for Diagnosing Neoplasms II |
| MX348362B (es) | 2008-03-31 | 2017-06-07 | Genentech Inc * | Composiciones y metodos para tratar y diagnosticar asma. |
| US20100221752A2 (en) | 2008-10-06 | 2010-09-02 | Somalogic, Inc. | Ovarian Cancer Biomarkers and Uses Thereof |
| US20130281876A1 (en) * | 2010-10-15 | 2013-10-24 | Medimmune Limited | Therapies for improving pulmonary function |
| TWI666447B (zh) | 2010-12-16 | 2019-07-21 | 建南德克公司 | 關於ｔｈ２抑制作用之診斷及治療 |
| WO2012158954A1 (en) | 2011-05-18 | 2012-11-22 | Medimmune, Llc | Methods of diagnosing and treating pulmonary diseases or disorders |
-
2015
- 2015-01-26 EP EP15740660.4A patent/EP3099323A4/en not_active Withdrawn
- 2015-01-26 RU RU2016134838A patent/RU2016134838A/ru not_active Application Discontinuation
- 2015-01-26 WO PCT/US2015/012885 patent/WO2015112970A1/en not_active Ceased
- 2015-01-26 CA CA2937387A patent/CA2937387A1/en not_active Abandoned
- 2015-01-26 CN CN201580005884.2A patent/CN105934254A/zh active Pending
- 2015-01-26 EP EP20158832.4A patent/EP3685857A1/en not_active Withdrawn
- 2015-01-26 JP JP2016566866A patent/JP2017509692A/ja active Pending
- 2015-01-26 SG SG11201606102UA patent/SG11201606102UA/en unknown
- 2015-01-26 MX MX2016009491A patent/MX2016009491A/es unknown
- 2015-01-26 KR KR1020167023637A patent/KR20160113700A/ko not_active Withdrawn
- 2015-01-26 US US15/114,467 patent/US20160363591A1/en not_active Abandoned
- 2015-01-26 BR BR112016017192A patent/BR112016017192A2/pt not_active IP Right Cessation
- 2015-01-26 AU AU2015209124A patent/AU2015209124A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN105934254A (zh) | 2016-09-07 |
| RU2016134838A3 (cg-RX-API-DMAC7.html) | 2018-09-27 |
| MX2016009491A (es) | 2017-01-13 |
| EP3099323A4 (en) | 2017-10-04 |
| JP2017509692A (ja) | 2017-04-06 |
| WO2015112970A1 (en) | 2015-07-30 |
| EP3685857A1 (en) | 2020-07-29 |
| BR112016017192A2 (pt) | 2017-10-10 |
| US20160363591A1 (en) | 2016-12-15 |
| CA2937387A1 (en) | 2015-07-30 |
| SG11201606102UA (en) | 2016-08-30 |
| AU2015209124A1 (en) | 2016-08-18 |
| EP3099323A1 (en) | 2016-12-07 |
| KR20160113700A (ko) | 2016-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016134838A (ru) | Дипептидил пептидаза-4 (dpp4/cd26) как периферический биомаркер активации il-13 в астматическом легком | |
| Santa Cruz et al. | Interleukin-6 is a biomarker for the development of fatal severe acute respiratory syndrome coronavirus 2 pneumonia | |
| Cao et al. | Pirfenidone ameliorates silica-induced lung inflammation and fibrosis in mice by inhibiting the secretion of interleukin-17A | |
| Maspero et al. | Type 2 inflammation in asthma and other airway diseases | |
| Jonstam et al. | Dupilumab reduces local type 2 pro‐inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis | |
| JP2017509692A5 (cg-RX-API-DMAC7.html) | ||
| Buhl et al. | Severe eosinophilic asthma: a roadmap to consensus | |
| O'Byrne et al. | Asthma progression and mortality: the role of inhaled corticosteroids | |
| Li et al. | CCL13 and human diseases | |
| JP2018533557A5 (cg-RX-API-DMAC7.html) | ||
| Geng et al. | Biologic therapies for allergic rhinitis and nasal polyposis | |
| Hodsman et al. | A phase 1, randomized, placebo‐controlled, dose‐escalation study of an anti‐IL‐13 monoclonal antibody in healthy subjects and mild asthmatics | |
| EP2627673B1 (en) | Therapies for improving pulmonary function | |
| Grainge et al. | Targeted therapeutics for severe refractory asthma: monoclonal antibodies | |
| Alt et al. | Antisomnogenic cytokines, quality of life, and chronic rhinosinusitis: a pilot study | |
| Hvidtfeldt et al. | Airway hyperresponsiveness reflects corticosteroid-sensitive mast cell involvement across asthma phenotypes | |
| Nicholson et al. | The effects of an anti–IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge | |
| Sposato et al. | Effects of omalizumab in severe asthmatics across ages: a real life Italian experience | |
| Huang et al. | Endotypes of severe allergic asthma patients who clinically benefit from anti‐IgE therapy | |
| Yilmaz et al. | Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilicasthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study | |
| Kleniewska et al. | Comparison of biomarkers in serum and induced sputum of patients with occupational asthma and chronic obstructive pulmonary disease | |
| US20250136676A1 (en) | Treatment Of Chronic Obstructive Pulmonary Disease With An Anti-Interleukin-33 Antibody | |
| JP2017506064A (ja) | ヒトペリオスチンを検出する新規アッセイ | |
| Kim et al. | Impact of the endothelial tight junction protein claudin-5 on clinical profiles of patients with COPD | |
| LIU et al. | Correlation between serum biomarkers and BODE index in patients with stable COPD |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190212 |